The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York, USA.
Clin Pharmacol Ther. 2011 Oct;90(4):509-18. doi: 10.1038/clpt.2011.173. Epub 2011 Sep 7.
Cardiovascular disease (CVD) has become the most common cause of mortality worldwide. Obesity, insufficient physical exercise, diabetes, and advancing age are major risk factors for developing cardiovascular disease that are currently increasing in prevalence. Nevertheless, significant progress has recently been made in the treatment of complex cardiovascular and coronary artery disease (CAD), with pharmacological management set to assume an increasingly important role. Other timely factors, such as the development of the polypill and high-level medical and political interest in advancing cardiovascular health, are driving forces that may help to make inroads into the global cardiovascular disease burden. In this article, we critically review the key challenges that we face in the coming decade as we strive to transition and apply our growing knowledge of complex CAD to promoting global cardiovascular health.
心血管疾病（CVD）已成为全球最常见的死亡原因。肥胖、身体活动不足、糖尿病和年龄增长是导致心血管疾病的主要危险因素，而这些因素的患病率正在不断上升。尽管如此，在治疗复杂心血管疾病和冠状动脉疾病（CAD）方面最近取得了重大进展，药物治疗将发挥越来越重要的作用。其他及时因素，如多效药丸的开发以及在促进心血管健康方面的高水平医学和政治兴趣，是推动我们努力过渡并应用我们对复杂 CAD 的日益增长的知识以促进全球心血管健康的驱动力。在本文中，我们批判性地回顾了在未来十年中我们面临的主要挑战，因为我们努力将我们对复杂 CAD 的日益增长的认识转化为促进全球心血管健康。
